About this trial
This project aims to activate dormant follicles in patients with premature ovarian insufficiency by injecting human chorionic gonadotropin (hCG) to explore the feasibility of a treatment plan that stimulates the growth of dormant follicles, not visible to the naked eye, to antral follicles visible under ultrasound, without visible follicle growth. The project also seeks to enable patients to conceive offspring carrying their own genetic material through in vitro fertilization (IVF) technology.
Eligibility criteria
Qualifiers
Females under 40 years of age with amenorrhea or oligomenorrhea for at least four months, and elevated follicle-stimulating hormone (FSH) levels > 25 IU/l on two separate occasions (with a 4-week interval);
Ultrasound (B-mode) indicating no antral follicle development in both ovaries for at least 3 months prior to study participation;
Those who agree to participate in this study and voluntarily sign the informed consent form.
Disqualifiers
Individuals over 40 years of age, or under 40 years of age with regular menstruation, normal ovulation, amenorrhea or oligomenorrhea for less than 4 months, and elevated follicle-stimulating hormone (FSH) levels < 25 IU/l on two or more separate occasions (with a 4-week interval);
Those with contraindications to the use of injectable human chorionic gonadotropin (HCG);
Those with asthma, epilepsy, heart disease, migraines, renal impairment, hypertension, or other diseases;
Patients deemed by the researcher as otherwise unsuitable for participation in this study."
Trial design
Treatments tested in this trial
- human chorionic gonadotropin